Technology inspired by 3D printing is already being introduced in hospitals and specialized pharmacies to produce personalized medicines tailored to individual patients. In her doctoral thesis at Åbo Akademi University, Mahsa Bahman investigated how the approach can improve dosing accuracy and make customised treatments more widely available.
Many medicines today are produced in standard doses, even though patients often have very different treatment needs. In her doctoral thesis in drug development at Åbo Akademi University, Mahsa Bahman investigated a technology that could make it easier to produce medicines tailored to individual patients, helping improve dose accuracy and access to treatment.
Personalised medicines are particularly important for children, older patients and others who require doses that are not commercially available. Today, healthcare professionals and caregivers may need to split tablets or adapt existing medicines, which can make accurate dosing difficult.
In her research, Mahsa Bahman studied a technology that uses a 3D printing-inspired manufacturing process to produce medicines in individually tailored doses. The system works by dispensing carefully measured amounts of a gel-like formulation, allowing pharmacists to create patient-specific treatments while maintaining consistent quality.
"Children often need medicine strengths that do not exist as commercial products. With this technology, pharmacists can manufacture dosage forms containing exactly the dose an individual child requires," says Mahsa Bahman.
The research examined how the technology can be used to manufacture a wide range of personalised medicines and evaluated factors such as dose accuracy, product quality, stability and consistency. The work also investigated how the technology performs in a hospital pharmacy environment.
The technology may also benefit older patients whose medication needs change over time, patients with rare diseases requiring specialised doses, hospital patients who need frequent dose adjustments, and situations where medicine shortages affect the availability of commercial products.
The thesis is also notable because it was carried out entirely within industry. Mahsa Bahman conducted her doctoral research as an industrial doctoral researcher at CurifyLabs, a Finnish health technology company and spin-off from Åbo Akademi University. The work illustrates how academic research and industry collaboration can help translate scientific advances into practical healthcare solutions.
Mahsa Bahman will publicly defend her doctoral thesis "Scalable Personalized Oral Medicines Through Semi-Solid Extrusion-Based Compounding Platform: Formulation Development, Quality Control, and Hospital Implementation" on 16 October 2026.
For further information, please contact:
Mahsa Bahman
email: mahsa.bahman@abo.fi
phone: +358 41 803 6010